Global Cord Blood (NYSE:CO) Earns Strong-Buy Rating from Analysts at StockNews.com

StockNews.com assumed coverage on shares of Global Cord Blood (NYSE:CO) in a research note released on Sunday. The brokerage issued a strong-buy rating on the medical research company’s stock.

Global Cord Blood Price Performance

Shares of NYSE CO opened at $1.25 on Friday. Global Cord Blood has a 52 week low of $2.03 and a 52 week high of $5.50. The business’s 50 day moving average price is $1.45 and its 200 day moving average price is $1.36. The firm has a market cap of $151.94 million, a P/E ratio of 1.95 and a beta of 0.16.

About Global Cord Blood

Global Cord Blood operates as a holding company, which engages in the provision of cord blood banking services. It provides cord blood processing and storage service. The company also offers cord blood collection, laboratory testing, hematopoietic stem cell processing and stem cell storage services. The firm preserves cord blood units donated by the public and provides matching services on such donated units and deliver matching units to patients in need of transplants.